...
首页> 外文期刊>Journal of Orthopaedic Surgery Research >Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomised controlled trials
【24h】

Combined use of intravenous and topical versus intravenous tranexamic acid in primary total knee and hip arthroplasty: a meta-analysis of randomised controlled trials

机译:静脉和局部静脉注射氨甲环酸联合静脉使用氨甲环酸在原发性全膝和髋关节置换术中的应用:一项随机对照试验的荟萃分析

获取原文
           

摘要

BackgroundThis meta-analysis aimed to evaluate the efficiency and safety of combined intravenous and topical methods of application versus single intravenous of tranexamic acid in primary total knee and hip arthroplasty. MethodsA systematic search was carried out in MEDLINE (from 1966 to 25 September 2016), PubMed (from 1966 to 25 September 2016), Embase (from 1980 to 25 September 2016), ScienceDirect (from 1985 to 25 September 2016) and the Cochrane Library. Only high-quality randomised controlled trials (RCT) were identified. Two authors independently performed data extraction and quality assessment of included studies. Meta-analysis was conducted using Review Manager 5.1 software. ResultsSix RCTs that included 687 patients met the inclusion criteria. The present meta-analysis indicated that there were significant differences in terms of total blood loss (MD?=??193.59, 95% CI ?338.06 to ?49.13, P =?0.009), transfusion rate (RD?=??0.07, 95% CI ?0.12 to ?0.03, P =?0.001), haemoglobin decline (MD?=??0.51, 95% CI ?0.83 to ?0.18, P =?0.01) and length of stay (MD?=??0.20, 95% CI ?0.38 to ?0.02, P =?0.03) between groups. ConclusionsCombined administration of tranexamic acid (TXA) in patients with total knee and hip arthroplasty was associated with significantly reduced total blood loss, transfusion requirements, postoperative haemoglobin decline and length of stay compared to single application alone but was not associated with prolonged operation time. Moreover, no adverse effects, such as superficial infection, deep vein thrombus (DVT) or pulmonary embolism (PE), were associated with TXA. We suggest that combined administration of TXA demonstrated excellent clinical efficacy and safety in patients with total knee and hip arthroplasty. More importantly, well-designed studies with larger sample size are needed to provide further reliable evidence for the combined use of TXA.
机译:背景本荟萃分析旨在评估静脉和局部联合应用方法与氨甲环酸在单次全膝和髋关节置换术中单次静脉使用的效率和安全性。方法在MEDLINE(1966年至2016年9月25日),PubMed(1966年至2016年9月25日),Embase(1980年至2016年9月25日),ScienceDirect(1985年至2016年9月25日)和Cochrane图书馆进行系统搜索。仅鉴定了高质量的随机对照试验(RCT)。两位作者分别对纳入研究进行了数据提取和质量评估。使用Review Manager 5.1软件进行荟萃分析。结果纳入687名患者的6项RCT符合纳入标准。本荟萃分析表明,在总失血量(MD≥193.59,95%CI 338.06至49.13,P = 0.009),输血率(RD≥0.07, 95%CI≤0.12至≤0.03,P =≤0.001),血红蛋白下降(MD≤≤0.51,95%CI≤0.83≤0.18,P =≤0.01)和住院时间(MD≤0.20) ,两组之间有95%的CI为0.38至0.02,P = 0.03)。结论与单独使用单药相比,全膝和髋关节置换术患者联合使用氨甲环酸(TXA)可以显着降低总失血量,输血量,术后血红蛋白下降和住院时间,但与延长手术时间无关。此外,TXA没有不良反应,例如浅表感染,深静脉血栓(DVT)或肺栓塞(PE)。我们建议在全膝关节和髋关节置换术患者中联合使用TXA表现出优异的临床疗效和安全性。更重要的是,需要精心设计的更大样本量的研究来为TXA的联合使用提供进一步的可靠证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号